New pill takes on tough blood cancers in first human trial
NCT ID NCT06501196
First seen Nov 01, 2025
Summary
This early-phase trial tests an experimental oral drug called BH-30236 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study first tests BH-30236 alone, then in combination with another drug, venetoclax. About 170 participants will be enrolled to check safety, dosing, and any signs of anti-cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion
RECRUITINGChicago, Illinois, 60611, United States
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Stanford Cancer Center
RECRUITINGPalo Alto, California, 94304, United States
-
Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
-
The Ohio State University Wexner Medical Center - James Cancer Hosp
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
University of Wisconsin Clinical Science Center
RECRUITINGMadison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BH-30236 (an oral CLK inhibitor) and venetoclax
What this could lead to
If successful, this could lead to a new oral treatment option for people with hard-to-treat leukemias and related blood cancers.
What could go wrong
This is a very early, first-in-human trial with a small number of participants. The drug may not work or could cause unexpected side effects. It is not a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.